Bionure Inc.’s MS Drug Candidate Shows Positive Results For Myelin Repair In Cell Culture Assay
5/27/2014 10:05:31 AM
PALO ALTO, Calif.--(BUSINESS WIRE)--Bionure Inc. today announced its drug candidate, BN201, was shown to promote myelination — the cellular process of repairing the protective sheath surrounding nerves that is damaged in people with multiple sclerosis (MS). The pre-clinical study was conducted in a novel cell-culture assay developed by the Myelin Repair Foundation (MRF) and assessed at the Foundation’s Translational Medicine Center under a previously announced collaborative agreement.
Help employers find you! Check out all the jobs and post your resume.
comments powered by